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Objective: Upon completion of this evaluation, successful learners will be able to manage patients with ulcerative colitis who are at
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BACKGROUND & AIMS: A random biopsy is recommended for
surveillance of ulcerative colitis (UC)-associated colorectal
cancer. However, a targeted biopsy might be more effective. We
conducted a randomized controlled trial to compare rates of
neoplasia detection by targeted vs random biopsies in patients
with UC. METHODS: We performed a study of 246 patients
with UC for 7 years or more, seen at 52 institutions in Japan
from October 1, 2008 through December 31, 2010. Patients
were randomly assigned to the random group (4 random
biopsies collected every 10 cm in addition to targeted biopsies,
n ¼ 122) or the target group (biopsies collected from locationsof suspected neoplasia, n ¼ 124). The primary end point was
the number of neoplastic lesions detected in a single surveil-
lance colonoscopy. We estimated the ratio and difference in the
mean number of neoplastic lesions between the groups. We
also evaluated the non-inferiority between the groups as an
exploratory study. A non-inferiority margin of 0.65 (0.13 of
0.20) was considered for the ratio of the mean number of
neoplastic lesions between groups. RESULTS: The mean num-
ber of biopsies found to contain neoplastic tissue per colo-
noscopy was 0.211 (24 of 114) in the target group and 0.168
(18 of 107) in the random group (ratio of 1.251; 95% conﬁ-
dence interval, 0.679–2.306). The lower limit was above the
non-inferiority margin of 0.65. Neoplasias were detected in
11.4% of patients in the target group and 9.3% of patients in
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ATthe random group (P ¼ .617). Larger numbers of biopsy sam-
ples per colonoscopy were collected in the random group (34.8
vs 3.1 in the target group; P < .001), and the total examination
time was longer (41.7 vs 26.6 minutes in the target group;
P < .001). In the random group, all neoplastic tissues found in
random biopsies were collected from areas of the mucosa with
a history or presence of inﬂammation. CONCLUSIONS: In a
randomized controlled trial, we found that targeted and
random biopsies detect similar proportions of neoplasias.
However, a targeted biopsy appears to be a more cost-effective
method. Random biopsies from areas without any signs of
present or past inﬂammation were not found to contain
neoplastic tissues. Clinical Trial Registry: UMIN000001608.CL
IN
ICKeywords: Dysplasia; Random Biopsy; Colonoscopy; IBD.n long-standing ulcerative colitis (UC), the risk forAbbreviations used in this paper: CRC, colorectal cancer; JSCCR,Icolorectal cancer (CRC) increases as disease duration
increases. The cumulative risk reaches 7.5%18.4% at 30
years after onset of the disease.1–3 We previously showed
that at an advanced stage, UC-associated CRC has poorer
survival rates than sporadic CRC.4 Therefore, early detection
of UC-associated CRC is essential for successful management
of long-standing UC. However, it is not always easy to
endoscopically identify UC-associated CRC or dysplasia, as
these lesions can be either invisible or very difﬁcult to
identify.5 Therefore, the guidelines recommend use of non-
targeted biopsy (random biopsy) for surveillance colonos-
copy, in which either 4 biopsy specimens for every 10 cm or
33 biopsy specimens are obtained.6–9 However, random
biopsy has been recognized to be costly and time-
consuming10 and targeted biopsy has recently received
much attention as an alternative.11–13 Studies have found
that 61%84% of neoplastic lesions could be visualized by
recent endoscopy14–16 and, therefore, the guidelines suggest
the possible use of targeted biopsy in place of random bi-
opsy to improve the efﬁcacy of surveillance.17,18 In targeted
biopsy, specimens are obtained only when endoscopic
ﬁndings indicate the possibility of neoplasia, leading to a
smaller number of samples and resulting in a more cost-
effective method. However, very few studies have so far
directly and prospectively compared the efﬁcacy of targeted
biopsy with that of random biopsy, and it still remains
controversial as to whether targeted biopsy should
completely replace random biopsy. Therefore, the Research
Group for Intractable Inﬂammatory Bowel Disease of the
Ministry of Health, Labour and Welfare of Japan and the
Japanese Society for Cancer of the Colon and Rectum (JSCCR)
conducted a randomized controlled trial to compare the 2
different biopsy methods. The aim of the present study
was to evaluate whether targeted biopsy would show the
comparable neoplasia detection rates with a random biopsy.Japanese Society for Cancer of the Colon and Rectum; UC, ulcerative
colitis.
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Study Design and Oversight
This trial was designed as an exploratory multicenter ran-
domized controlled trial to provide an estimate of the meannumber of neoplastic biopsy samples per colonoscopy for a
targeted biopsy and a random biopsy in cancer surveillance for
long-standing UC patients (Figure 1). The non-inferiority was
additionally evaluated with a non-inferiority margin of 0.65 for
the ratio of mean number of neoplastic lesions identiﬁed
between groups. The protocol was set up by the Research
Group for Intractable Inﬂammatory Bowel Disease of the
Ministry of Health, Labour and Welfare of Japan and JSCCR. This
study was approved by the ethics committee of JSCCR and the
Institutional Review Boards of all participating institutions and
was conducted in accordance with the Declaration of Helsinki.
All participants gave their written informed consent for study
participation. An independent data and safety monitoring
committee assessed the study data. All serious adverse events
were reported to an independent data and safety monitoring
committee. The trial is registered at the UMIN Clinical Trial
Registry as UMIN000001608 (http://www.umin.ac.jp/ctr/
index-j.htm) and the study protocol has been described
previously.19
Sites and Patients
All of the participating sites (52 Japanese institutions) were
members of the Research Group for Intractable Inﬂammatory
Bowel Disease of the Ministry of Health, Labour and Welfare of
Japan or JSCCR. We recruited UC patients (left-sided colitis and
pancolitis) for whom 7 years or more had passed since onset of
the disease. Inclusion and the exclusion criteria are shown in
Supplementary Table 1.20,21
Study Interventions
We randomly assigned the patients to the targeted biopsy
group (target group) or the step biopsy group (random group)
after conﬁrming the inclusion and exclusion criteria with the
Data Center, Department of Preventive Medicine and Public
Health, Keio University. Using stratiﬁed allocation, the Data
Center deﬁnes the facilities and the severity of UC as stratiﬁ-
cation factors to randomly assign the patients into the target
group or the random group. Unique random sequence, which
had been generated by the Data Center, was sequentially
applied to each patient allocation. The detailed procedures of
randomization were not disclosed to researchers at the
participating sites. The results of the assignment were not
blinded to researchers. In the target group, specimens were
obtained by a targeted biopsy. In addition, at least 1 biopsy
sample was obtained in the lower rectum, even when no
ﬁndings suggesting the presence of neoplasia existed. In the
random group, 4 random biopsies were obtained every 10 cm.
In addition, a targeted biopsy was performed in regions sus-
pected of neoplasia. Panchromoendoscopy was not performed
routinely because the study was concluded before the SCENIC
(Surveillance for Colorectal Endoscopic Neoplasia Detection
Figure 1. Study design. The patients were randomly assigned to either the targeted biopsy group (target group) or the random
biopsy group (random group). In the target group, specimens were obtained by a targeted biopsy. In addition, at least 1 biopsy
sample was obtained in the lower rectum, even though there were no ﬁndings suspicious for neoplasia. In the random group, 4
random biopsies were obtained every 10 cm. In addition, a targeted biopsy was performed from regions suspicious of
neoplasia. (A) Two dysplastic lesions were detected by targeted biopsies. A biopsy specimen from the ﬂat elevated lesion on 1
o’clock direction showed high-grade dysplasia, while that from the polypoid lesion in the center revealed low-grade dysplasia.
(B) Indigo carmine dye spraying enhanced dysplastic lesions detected by white light endoscopy shown in (A). (C) Areas
showing clear vascular patterns without any evidence of present or past inﬂammation, which could be omitted when
performing a random biopsy. (D) Areas with ulcer scars, which may be better surveyed by a random biopsy.
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International Consensus Recommendations) statements had
been published. However, in both groups, normal endoscopy
and chromoendoscopy were performed for any lesions sus-
pected of being neoplasia. Although high-deﬁnition colonoscopy
was only employed at the endoscopists’ discretion and based
on the institutions’ availability, the majority of institutions
utilized high-deﬁnition white-light endoscopes in 100% of
cases, while the rest of the institutions used them whenever
they were available. The number of targeted biopsy samples
was not particularly limited, but the characteristics of the bio-
psied areas were noted to be protruding lesions, ﬂat lesions,
depressed lesions, or others.Outcomes
The primary end point was the number of neoplastic lesions
detected in a single surveillance colonoscopy. The secondary
end points were the detection rate of patients with neoplasia,
examination time, number of biopsies in each examination,
incidence of complications requiring special treatments, andrisk factors for neoplasia. At the time of registration and after
the performance of surveillance colonoscopy, the patient clin-
ical data were reported to the Data Center. Each participating
institution submitted 4 unstained sections of all biopsy speci-
mens to the Data Center, which were stained for H&E, p53, and
Ki67. All biopsied specimens were centrally evaluated histo-
pathologically by 3 specialized pathologists. The pathologic
ﬁndings were categorized as the absence of neoplasia,
low-grade dysplasia, and high-grade dysplasia.22 In the event of
a discrepancy among the pathologists, the ﬁnal diagnosis was
made based on a discussion. The ﬁnal pathologic diagnoses
were sent to each institution.Statistical Methods
As noted previously in the study protocol, we set the total
sample size for this study at 200 to estimate the difference in
the primary end point with the one side length of the 95%
conﬁdence interval (CI) precision of 0.11.19 Mean number of
neoplasias per colonoscopy was expected to be the same
between the groups, and non-inferiority would be accepted
December 2016 Targeted Biopsy for the Surveillance of UC 1125
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ATstatistically if the mean number of neoplasias in the target
group was at least 65% (0.13 of 0.2) of the mean number of
neoplasias per colonoscopy in the random group.
Analyses were performed in the full analysis set. In the
primary end point assessment, we estimated the ratio and
difference in mean number of neoplastic lesions between the
random biopsy and target biopsy groups with a 95% CI. The
95% CIs of the ratio and the difference in mean number were
calculated based on the Poisson distribution. For the secondary
end points, Wilcoxon rank sum test and c2 test were used, as
appropriate. The non-inferiority P value was 1-sided and the
other P values were 2-sided; those <.025 for 1-sided tests and












Duration of disease, n
<10 y 17 21
10 y 97 86
Disease extent, n
Left-sided colitis 44 27
Pancolitis 64 75
Others 6 5
Simple clinical activity index, n
Score 8 114 107
Score >8 0 0





Body mass index, kg/m2, mean (SD) 22.9 (3.1) 22.4 (3.1)
Stool frequency, n/d, mean (SD) 2.0 (1.3) 2.1 (1.1)
Hospitalizations for UC, n, mean (SD) 1.3 (1.4) 1.9 (1.9)




History of use of immunomodulatory
drugs in the past year, n
Present 29 34
Absent 84 73
Primary sclerosing cholangitis, n
Present 0 0
Absent 114 106
Family history of cancer, n
Present 19 22
Absent 95 84
Family history colorectal cancer, n
Present 5 4
Absent 108 100
Maintenance therapy at the time
of examination, n
Present 108 101
Absent 5 4signiﬁcant. All analyses were performed with SAS software,
version 9.4 (SAS Institute Inc, Cary, NC) and R, version 3.1.2.CL
IN
ICResults
A total of 250 patients were assessed for eligibility
(Supplementary Appendix). Four patients were determined
to be ineligible and 246 patients underwent randomization.
One hundred and twenty-four patients were assigned to
the target group and 122 patients to the random group.
Twenty-ﬁve patients were ineligible for the full analysis set,
therefore, 114 patients in the target group and 107 patients
in the random group were ultimately analyzed. The baseline
characteristics of the 2 groups were similar (Table 1).
Patients from 34 institutions were enrolled in this study
between October 1, 2008 and December 31, 2010.
A total of 42 biopsy samples were found to demonstrate
neoplasia (Figures 3 and 4, Table 2, and Supplementary
Figure 1). The number of low-grade dysplasias was 23 in
the target group and 18 in the random group, and the
number of high-grade dysplasias was 1 in the target groupFigure 2. The mean number of biopsy samples with neoplasia
(A) and the detection rate of patients with neoplasia (B). (A)
The mean number of biopsy samples with neoplasia in each
surveillance colonoscopy was 0.211 (24 of 114) in the target
group and 0.168 (18 of 107) in the random group, thus
showing no signiﬁcant difference (P ¼ .423). Focusing on a
targeted biopsy, there was a signiﬁcant difference between
the 2 groups. The target group showed a signiﬁcantly higher
mean number of samples with neoplasia detected by a
targeted biopsy than the random group (0.193 vs 0.037;
P < .001). (B) The detection rate of patients with neoplasia
was 11.4% (13 of 114) and 9.3% (10 of 107) in the target
group and random group, respectively, showing no signiﬁ-
cant difference. A higher percentage of patients had a diag-
nosis of neoplasia based on the ﬁndings of a targeted biopsy
in the target group than in the random group (P ¼ .052).
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samples with neoplasia in each surveillance colonoscopy
was 0.211 (24 of 114) in the target group and 0.168 (18 of
107) in the random group, showing no statistical signiﬁ-
cance (Figure 2). The ratio between the groups was 1.251
(95% CI, 0.679 to 2.306). The lower limit was above the
non-inferiority margin of 0.65 (Supplementary Figure 2).
The difference between the 2 groups was 0.042 (95%
CI, 0.209 to 0.294). The target group showed a signiﬁ-
cantly higher mean number of samples with neoplasia
detected by targeted biopsy than the random group (0.193
vs 0.037; P < .001). The detection rate of the patients with
neoplasia was 11.4% (13 of 114) in the target group and
9.3% (10 of 107) in the random group, showing no signif-
icant difference (P ¼ .617). However, there was a signiﬁcant
difference in the detection rate of patients with neoplasia by
targeted biopsy. A higher percentage of patients had a
diagnosis of neoplasia by targeted biopsy in the target group
than in the random group (10.5% vs 3.7%; P ¼ .052).Figure 3. Distribution of random biopsied samples with neopla
random biopsy were obtained from mucosal regions with either h
biopsied samples obtained from mucosal regions without his
random group. However, in the target group, 1 sample obtain
inﬂammation showed neoplasia.There was a close relationship between neoplasia and
inﬂammation (Figure 3). In the random group, all
neoplastic random biopsy samples were obtained from
mucosa with either history or presence of inﬂammation
(100% [13 of 13]), except for 1 sample with unknown
inﬂammation status. In other words, no neoplastic random
biopsy samples were obtained from mucosa without either
history or presence of inﬂammation in the random group
(0% [0 of 709]. However, in the target group, 1 random
biopsy sample obtained from the rectum without
inﬂammation showed neoplasia.
The proportion of neoplasia among the biopsied samples
was signiﬁcantly higher in the target group (6.9% [24
of 350]) than in the random group (0.5% [18 of 3725];
P < .001). Mean number of biopsy samples in each
colonoscopy was signiﬁcantly larger in the random group
than in the target group (34.8 vs 3.1; P < .001). The total
examination time was signiﬁcantly longer in the random
group than in the target group (41.7 vs 26.6 minutes;sia. In the random group, all neoplastic samples taken by a
istory or presence of inﬂammation. In other words, all random
tory or presence of inﬂammation were non-neoplasia in the
ed by random biopsy from a mucosa in the rectum without




biopsies. (A, B) A ﬂat
granular lesion (0IIa, low-
grade dysplasia) (A: white
light; B: indigo carmine
dye spraying). (C, D) A
coarse nodular lesion
(0IIa, low-grade dysplasia)
(C: white light; D: narrow
band imaging). (E, F) A ﬂat
depressed lesion (0IIc,
low-grade dysplasia) (E:
white light; F: indigo
carmine dye spraying).





ATP < .001). In total, the number of neoplastic lesions in the
right, transverse, descending, sigmoid colon, and rectum
was 5, 5, 3, 19, and 10, respectively (Supplementary
Figure 3). In the target group, 77.3% of the neoplastic
lesions (17 of 22) were protruded lesions, 4.5% (1 of 22)
were ﬂat lesions and 18.2% (4 of 22) were stenosis
(Supplementary Figure 4, Supplementary Table 2). Physi-
cian experience with surveillance colonoscopy was compa-
rable between the 2 groups (mean, 12.7 [SD 5.7] years in the
target group and mean, 13.7 [SD 6.1] years in the random
group; P ¼ .201). There were no complications requiring
any special treatments in either group. Univariate analysis
revealed the duration of the disease to be a risk factor for
neoplasia (Supplementary Table 4).Discussion
The target group was non-inferior to the random group
with respect to the mean number of neoplasia detected per
colonoscopy. Furthermore, the overall detection rates of
neoplasia per patient showed no signiﬁcant difference be-
tween the 2 groups, and detection rates in the present study
were in line with results reported previously (range, 8.7%
12.3%).2,16 The examination time was signiﬁcantly longer in
the random group (41.7 vs 26.6 minutes; P < .001) and
mean number of biopsy samples per each examination was
signiﬁcantly larger in the random group than in the target
group (34.8 vs 3.1; P < .001). Recent guidelines recommend
the use of a target biopsy, however, there has been no
concrete evidence to show that a target biopsy should









Neoplastic lesions per colonoscopy, n 0.211 0.168
Patients with neoplasia detected, n (%) 13 (11.4) 10 (9.3)
The proportion of neoplasia per
biopsy specimen
Neoplastic lesions, n (%) 24 (6.9) 18 (0.5)
Biopsy specimens taken, n 350 3725
Neoplastic lesions detected, n 24 18
By targeted biopsy 22 4
By random biopsy 2 14
Location, n (%)
Ascending, cecum 2 (8.3) 3 (16.7)
Transverse 2 (8.3) 3 (16.7)
Descending 3 (12.5) 0 (0)
Sigmoid 12 (50.0) 7 (38.9)
Rectum 5 (20.8) 5 (27.8)
Conﬁguration, n (%)
Protruded 17 (77.3) —
Flat 1 (4.5) —
Stricture 4 (18.2) —
Total examination time, min 26.6 41.7
Low-grade dysplasia, n 23 18
High-grade dysplasia, n 1 0
Invasive cancer, n 0 0
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domized controlled trials have evaluated the different
methods of surveillance.12,23–26 Kiesslich et al12,23 found
that chromoendoscopy or chromoendoscopy-guided endo-
microscopy can improve the efﬁcacy of surveillance. van den
Broek et al24 found autoﬂuoroscence imaging improved
detection of neoplasia in surveillance. However, these
studies did not directly compare the efﬁcacy of a random
biopsy with a target biopsy. The present study performed a
direct comparison between targeted biopsy and random
biopsy in a randomized controlled trial and found that both
procedures show comparable rates of neoplasia detection.
Furthermore, no severe complications occurred that
required treatment in either group. Taken together, it is
suggested that a targeted biopsy may be more cost-effective
and may be used as an alternative to performing a random
biopsy in the surveillance of UC.
The use of targeted biopsy by omitting a random biopsy
may increase the potential risk of missing neoplastic lesions
because neoplastic lesions are sometimes difﬁcult to iden-
tify. However, contrary to our expectations, the target group
showed an even larger mean number of neoplastic samples
per colonoscopy (0.211 vs 0.168) and a higher detection
rate of patients with neoplasia (11.4% vs 9.3% per patient),
although these differences did not reach statistical signiﬁ-
cance. Furthermore, focusing on the detection rate of
neoplasia by a targeted biopsy, the target group showed a
signiﬁcantly higher mean number of samples with neoplasia
per colonoscopy than the random group (0.193 vs 0.037;P < .001). In addition, a higher percentage of patients had a
diagnosis of neoplasia by a targeted biopsy in the target
group than in the random group (10.5% vs 3.7%; P ¼ .052).
The precise reason for these differences is unclear. How-
ever, one possible reason may be that, in the random group,
bleeding due to a random biopsy may disturb precise
endoscopic examinations, thereby making a targeted biopsy
more difﬁcult. Another possibility is that a random biopsy
takes a larger number of biopsies and needs a longer ex-
amination time, which may distract endoscopists from
performing meticulous examinations. Therefore, endo-
scopists might overlook some suspicious lesions that would
normally be obtained by a targeted biopsy.
Previous studies found that 1088–2707 random biopsies
are necessary to ﬁnd 1 dysplasia,16,25,27 while another study
showed that no neoplasia was found in 2904 random biopsy
samples.11 On average, Rutter et al10 reported that 1266
random biopsies are necessary to detect 1 neoplasia. In the
present study, about 250 random biopsies were needed to
ﬁnd 1 neoplasia in the random group. On the other hand,
only 14 targeted biopsies were needed to ﬁnd neoplasia in
the target group. Other studies also show that a smaller
number of specimens are needed to ﬁnd 1 neoplasia by a
targeted biopsy.11,16 These results show that a targeted
biopsy appears to be a more useful and effective method for
time and cost-effectiveness.
Endoscopic inﬂammation seemed to be important to
improve the efﬁcacy of a random biopsy. In the random
group, all 13 neoplastic random biopsy samples were
obtained from mucosa with the presence or history of
inﬂammation. In other words, not even a single sample from
mucosa without the presence or history of inﬂammation
showed neoplasia (0% [0 of 709]), which suggests the
possibility that random biopsy from mucosa without the
presence or a history of inﬂammation can be omitted. If we
follow this method, we could have decreased the number of
random biopsies from 3456 to 2747 in the present study.
However, it should also be noted that 1 of the 2 random
biopsy samples that demonstrated neoplasia in the target
group was taken from rectal mucosa without inﬂammation.
According to the present protocol, 1 random biopsy was to
be taken from the rectum in the target group because
neoplasia is frequently located in the rectum in UC. This
protocol was originally carried out in our previous study.13
Taken together, these results suggest that when performing
a targeted biopsy, an additional random biopsy from the
rectum is recommended, even when there is no evidence or
a history of any inﬂammation.
A clinicopathologic analysis revealed that the location of
neoplasia shows a distal predominance, the majority of
neoplastic lesions detected by a targeted biopsy were pro-
truded lesions, and the risk factor for neoplasia was the
duration of the disease, all of which is in line with previous
studies.1,2,4
There are several limitations in the present study. First,
surveillance colonoscopy was conducted once for each
patient during the study period. No data on subsequent
colonoscopy after 1 or 2 years were collected. Therefore,
this may raise some concern that neoplastic lesions may





AThave been missed during surveillance colonoscopy, which
might have been detected during subsequent colonoscopy.
Second, we did not incorporate pancolonic chromoendo-
scopy in our protocol because it was not generally recom-
mended at the time we made the protocol. Our protocol
paper was published in August 2010, which was before the
British Society of Gastroenterology guideline was published.
However in the recent SCENIC statements, many experts
recommend the use of chromoendoscopy,28 and probably
panchromoendoscopy is now one of the choices for UC
surveillance. The incorporation of pancolonic chromoendo-
scopy might have changed our result. At the same time,
however, controversy still existed regarding the use of
chromoendoscopy because one recent large cohort paper
from the Netherlands demonstrated that chromoendoscopy
did not increase the dysplasia detection rate.29 Lastly, the
number of patients in this trial was another limitation. We
could not plan this trial in an ideal setting, as non-inferiority
because of difﬁculty in recruiting patients. However, the
mean number of neoplastic lesions of the target group was
larger than that of the random group, and the 1-sided
P value for non-inferiority was <.05, from which we can
consider our hypothesis was supported.
In conclusion, a targeted biopsy is as effective as a
random biopsy for the detection of neoplasia in surveillance
for UC. Considering cost-effectiveness, a targeted biopsy
seems to be more effective than a random biopsy. When
performing a targeted biopsy, it is recommended that a
random biopsy sample be taken from the rectum. On the
other hand, when performing a random biopsy, obtaining
biopsy specimens from areas without any signs of present
or past inﬂammation can be omitted, which can reduce the
number of unnecessary biopsies and increase the efﬁcacy of
the random biopsy.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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